<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680379</url>
  </required_header>
  <id_info>
    <org_study_id>2016-1177</org_study_id>
    <nct_id>NCT02680379</nct_id>
  </id_info>
  <brief_title>Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome</brief_title>
  <acronym>LovaMiX</acronym>
  <official_title>A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMix)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FRAXA Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Lovastatin, Minocycline and the combination
      Lovastatin/Minocycline are effective in treating behavioral symptoms in Fragile X
      individuals.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Aberrant Behavior Checklist-Community (ABC-C) total score at 8,12 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 12 weeks, 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale improvement (CGI-I)</measure>
    <time_frame>baseline, 8 weeks, 12 weeks, 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Social Responsiveness Scale (SRS) at 8 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety, depression and mood scale (ADAMS), change from baseline to 8 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at 8 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Rating Inventory of Executive Function (BRIEF)</measure>
    <time_frame>Before treatment and at the end of treatment (weeks 20)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Vineland II; adaptive behaviour scale at 20 weeks</measure>
    <time_frame>baseline, 20 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>(optional) Change in brain activity using Functional Magnetic Resonance Imaging (fMRI) at 8 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 20 weeks</time_frame>
    <description>fMRI is a non-invasive method of assessing brain activity by detecting signal changes in blood flow and oxygenation known as BOLD (Blood-Oxygen-Level Dependent) contrast imaging.</description>
  </other_outcome>
  <other_outcome>
    <measure>(optional) Change in neurochemistry using Transcranial Magnetic Stimulation (TMS) at 8 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 20 weeks</time_frame>
    <description>Using an unpainful magnetic stimulation on the primary motor cortex, TMS will be used to assess intracortical facilitation and inhibition, corresponding respectively to glutamate and GABAergic processes.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>Minocycline, then Minocycline/Lovastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take minocycline then a combined treatment of minocycline/lovastatin for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovastatin, then Minocycline/Lovastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will lovastatin then a combined treatment of minocycline/lovastatin for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline, then Minocycline/Lovastatin</intervention_name>
    <description>Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.</description>
    <arm_group_label>Minocycline, then Minocycline/Lovastatin</arm_group_label>
    <other_name>Minocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin, then Minocycline/Lovastatin</intervention_name>
    <description>Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.</description>
    <arm_group_label>Lovastatin, then Minocycline/Lovastatin</arm_group_label>
    <other_name>Mevacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a molecular diagnosis for fragile X syndrome

          -  The participant must be accompanied by his sponsor who may be the person having
             parental authority, his tutor (for minor) or representative (for major inapt)

          -  Identify a caregiver who spends at least six hours per day with the participant. The
             sponsor and the caregiver may be the same person

          -  Intelligence quotient (IQ) &lt; 70

          -  ABC-C &gt; 20

          -  CGI-S ≥ 4

        Exclusion Criteria:

          -  Pregnant or breastfeeding subjects

          -  Intolerance / allergy previous to statins, minocycline or tetracycline

          -  Taking lovastatin or taking minocycline in the last 12 weeks

          -  Personal history of myopathy, myalgia or high creatine kinase (CK) level

          -  Renal disease / liver / hepatorenal balance disturbed, as antinuclear antibody (ANA) &gt;
             40

          -  Concomitant use of prohibited drugs *

          -  Taking two or more psychoactive medications except anticonvulsants

          -  Untreated hypothyroidism and / or uncontrolled

          -  Any other active medical condition

          -  Amendment psychoactive treatment in the last 6 weeks prior to randomization *
             Prohibited drugs include other hypolipemic including gemfibrozil (or other fibrates)
             and niacin (nicotinic acid), angiotensin converting enzyme (ACE), cyclosporine,
             danazol, amiodarone, verapamil and inhibitors P450 (CYP3A4) (itraconazole,
             ketoconazole, erythromycin, clarithromycin, telithromycin, inhibitors of HIV protease
             and nefazodone).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Corbin, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fragile X Clinic, Centre de recherche du CHUS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francois Corbin, MD/PhD</last_name>
    <email>info@cliniquexfragilequebec.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de Recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Champigny, Research Coordinator, M.D., M.Sc. student</last_name>
      <phone>(1) 819-346-1110</phone>
      <phone_ext>14402 or 72782</phone_ext>
      <email>info@cliniquexfragilequebec.org</email>
    </contact>
    <investigator>
      <last_name>Francois Corbin, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://cr.chus.qc.ca/en/axes/mother-child/chercheurs/francois-corbin-m-d-ph-d/</url>
    <description>Investigator profile</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Francois Corbin</investigator_full_name>
    <investigator_title>Dr Francois Corbin, MD, PHD, FRCPC</investigator_title>
  </responsible_party>
  <keyword>Fragile X Syndrome</keyword>
  <keyword>Autism</keyword>
  <keyword>FMR1</keyword>
  <keyword>FRAXA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fragile X Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

